These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

133 related articles for article (PubMed ID: 15156413)

  • 1. The role of nitric oxide in the development of diabetic angiopathy.
    Santilli F; Cipollone F; Mezzetti A; Chiarelli F
    Horm Metab Res; 2004 May; 36(5):319-35. PubMed ID: 15156413
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Von Willebrand factor in diabetic angiopathy.
    Kessler L; Wiesel ML; Attali P; Mossard JM; Cazenave JP; Pinget M
    Diabetes Metab; 1998 Sep; 24(4):327-36. PubMed ID: 9805643
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Nitric oxide dynamics and endothelial dysfunction in type II model of genetic diabetes.
    Bitar MS; Wahid S; Mustafa S; Al-Saleh E; Dhaunsi GS; Al-Mulla F
    Eur J Pharmacol; 2005 Mar; 511(1):53-64. PubMed ID: 15777779
    [TBL] [Abstract][Full Text] [Related]  

  • 4. A possible involvement of crosstalk between advanced glycation end products (AGEs) and asymmetric dimethylarginine (ADMA), an endogenous nitric oxide synthase inhibitor in accelerated atherosclerosis in diabetes.
    Yamagishi S; Ueda S; Okuda S
    Med Hypotheses; 2007; 69(4):922-4. PubMed ID: 17368960
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Nitric oxide and vascular responses in Type I diabetes.
    Chan NN; Vallance P; Colhoun HM
    Diabetologia; 2000 Feb; 43(2):137-47. PubMed ID: 10753034
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Endothelial nitric oxide in diabetes mellitus: too much or not enough?
    Farkas K; Sármán B; Jermendy G; Somogyi A
    Diabetes Nutr Metab; 2000 Oct; 13(5):287-97. PubMed ID: 11105972
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Vascular endothelial dysfunction: a tug of war in diabetic nephropathy?
    Balakumar P; Chakkarwar VA; Krishan P; Singh M
    Biomed Pharmacother; 2009 Mar; 63(3):171-9. PubMed ID: 18823739
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Endothelial dysfunction in diabetes mellitus.
    Cosentino F; Lüscher TF
    J Cardiovasc Pharmacol; 1998; 32 Suppl 3():S54-61. PubMed ID: 9883749
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Nitric oxide in the pathogenesis of vascular disease.
    Li H; Förstermann U
    J Pathol; 2000 Feb; 190(3):244-54. PubMed ID: 10685059
    [TBL] [Abstract][Full Text] [Related]  

  • 10. [Study on the altered nitric oxide metabolism in experimental diabetes].
    Tábi T; Soltész Z; Magyar K; Szöko E
    Acta Pharm Hung; 2006; 76(1):19-23. PubMed ID: 17094672
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Endothelial dysfunction, atherosclerosis and diabetes.
    Najemnik C; Sinzinger H; Kritz H
    Acta Med Austriaca; 1999; 26(5):148-53. PubMed ID: 11512191
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Vascular endothelial growth factor receptor-2 and low affinity VEGF binding sites on human glomerular endothelial cells: Biological effects and advanced glycosilation end products modulation.
    Pala L; Cresci B; Manuelli C; Maggi E; Yamaguchi YF; Cappugi P; Rotella CM; Giannini S
    Microvasc Res; 2005 Nov; 70(3):179-88. PubMed ID: 16271941
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Coenzyme Q10 and diabetic endotheliopathy: oxidative stress and the 'recoupling hypothesis'.
    Chew GT; Watts GF
    QJM; 2004 Aug; 97(8):537-48. PubMed ID: 15256611
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Role of advanced glycation end products (AGEs) and their receptor (RAGE) in the pathogenesis of diabetic microangiopathy.
    Yamagishi S; Takeuchi M; Inagaki Y; Nakamura K; Imaizumi T
    Int J Clin Pharmacol Res; 2003; 23(4):129-34. PubMed ID: 15224502
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Why does diabetes mellitus increase the risk of cardiovascular disease?
    Shahab A
    Acta Med Indones; 2006; 38(1):33-41. PubMed ID: 16479030
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Analysis of NO-synthase expression and clinical risk factors in human diabetic nephropathy.
    Hohenstein B; Hugo CP; Hausknecht B; Boehmer KP; Riess RH; Schmieder RE
    Nephrol Dial Transplant; 2008 Apr; 23(4):1346-54. PubMed ID: 18065828
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Nitric oxide: ocular blood flow, glaucoma, and diabetic retinopathy.
    Toda N; Nakanishi-Toda M
    Prog Retin Eye Res; 2007 May; 26(3):205-38. PubMed ID: 17337232
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Gene therapy of endothelial nitric oxide synthase and manganese superoxide dismutase restores delayed wound healing in type 1 diabetic mice.
    Luo JD; Wang YY; Fu WL; Wu J; Chen AF
    Circulation; 2004 Oct; 110(16):2484-93. PubMed ID: 15262829
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Multifunctional drugs for endothelial dysfunction in diabetes and glaucoma.
    Wood PL
    IDrugs; 2003 Apr; 6(4):360-7. PubMed ID: 12789607
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Oxidant stress impairs in vivo reendothelialization capacity of endothelial progenitor cells from patients with type 2 diabetes mellitus: restoration by the peroxisome proliferator-activated receptor-gamma agonist rosiglitazone.
    Sorrentino SA; Bahlmann FH; Besler C; Müller M; Schulz S; Kirchhoff N; Doerries C; Horváth T; Limbourg A; Limbourg F; Fliser D; Haller H; Drexler H; Landmesser U
    Circulation; 2007 Jul; 116(2):163-73. PubMed ID: 17592079
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 7.